Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Breast Cancer: Update Bulletin [August 2017]

Product Code:
596200925
Publication Date:
August 2017
Format:
PDF
Price:
€975

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of breast cancer (BC). Topics covered include expert opinions on: Roche announcing results from the Phase III APHINITY study of Perjeta (pertuzumab) as an adjuvant therapy for BC; Merck & Co. announcing data from the Keytruda (pembrolizumab) I-SPY 2 study; as well as the US approval and launch of Nerlynx (neratinib; Puma Biotechnology).

Business Questions:

• How do KOLs regard Perjeta’s magnitude of benefit in the APHINITY trial?
• According to KOLs, in which patients will Perjeta be prescribed?
• What are KOLs’ views on Keytruda as a neoadjuvant therapy in triple-negative BC?
• How do KOLs view checkpoint inhibitors in general as potential therapies for BC?
• How do experts foresee Nerlynx being prescribed in the treatment of BC?
• What factors, if any, are likely to impact Nerlynx’s uptake?




customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved